Pharmacoeconomic study of chemotherapy for gastric cancer

analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy

Katsumi Tanaka, Tsutomu Kaetsu, Satoshi Suzuki, Mitsuo Kusano, Shuichi Yajima, Hiroyuki Sakamaki, Shunya Ikeda, Naoki Ikegami, Jun Ichiro Murayama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To evaluate the economic impact of TS-1, an oral fluoropyrimidine, on the treatment of gastric cancer, the medical costs required for TS-1 treatment were compared with those for the conventional chemotherapy employed before the launch of TS-1 in patients with advanced and recurrent gastric cancer. The medical costs for 13 patients receiving TS-1 and 10 patients undergoing the conventional chemotherapy were extracted from the ordering system data, and the costs were compared using the fee schedule of the Japanese national health insurance. The monthly medical costs for the TS-1 group and conventional chemotherapy group were 327, 640 +/- 47,647 (mean +/- SE) yen and 852,874 +/- 62,412 yen, respectively. Medical costs appeared to have decreased because TS-1 is an oral preparation, permitting an easy transfer from inpatient treatment to ambulatory treatment, and because only small amounts of medication and blood transfusion were used for supportive care. Consequently, the medical costs for the TS-1 group were significantly lower than for the conventional chemotherapy group. Therefore, the administration of TS-1 leads to a reduction in medical costs.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number1
Publication statusPublished - 2003 Jan

Fingerprint

Pharmaceutical Economics
Stomach Neoplasms
Costs and Cost Analysis
Drug Therapy
Therapeutics
Fee Schedules
titanium silicide
National Health Programs
Information Systems
Blood Transfusion
Inpatients
Economics

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Pharmacoeconomic study of chemotherapy for gastric cancer : analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy. / Tanaka, Katsumi; Kaetsu, Tsutomu; Suzuki, Satoshi; Kusano, Mitsuo; Yajima, Shuichi; Sakamaki, Hiroyuki; Ikeda, Shunya; Ikegami, Naoki; Murayama, Jun Ichiro.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 30, No. 1, 01.2003, p. 73-80.

Research output: Contribution to journalArticle

Tanaka, K, Kaetsu, T, Suzuki, S, Kusano, M, Yajima, S, Sakamaki, H, Ikeda, S, Ikegami, N & Murayama, JI 2003, 'Pharmacoeconomic study of chemotherapy for gastric cancer: analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 30, no. 1, pp. 73-80.
Tanaka, Katsumi ; Kaetsu, Tsutomu ; Suzuki, Satoshi ; Kusano, Mitsuo ; Yajima, Shuichi ; Sakamaki, Hiroyuki ; Ikeda, Shunya ; Ikegami, Naoki ; Murayama, Jun Ichiro. / Pharmacoeconomic study of chemotherapy for gastric cancer : analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2003 ; Vol. 30, No. 1. pp. 73-80.
@article{4c017831e51e4217a5a016034bd3b25c,
title = "Pharmacoeconomic study of chemotherapy for gastric cancer: analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy",
abstract = "To evaluate the economic impact of TS-1, an oral fluoropyrimidine, on the treatment of gastric cancer, the medical costs required for TS-1 treatment were compared with those for the conventional chemotherapy employed before the launch of TS-1 in patients with advanced and recurrent gastric cancer. The medical costs for 13 patients receiving TS-1 and 10 patients undergoing the conventional chemotherapy were extracted from the ordering system data, and the costs were compared using the fee schedule of the Japanese national health insurance. The monthly medical costs for the TS-1 group and conventional chemotherapy group were 327, 640 +/- 47,647 (mean +/- SE) yen and 852,874 +/- 62,412 yen, respectively. Medical costs appeared to have decreased because TS-1 is an oral preparation, permitting an easy transfer from inpatient treatment to ambulatory treatment, and because only small amounts of medication and blood transfusion were used for supportive care. Consequently, the medical costs for the TS-1 group were significantly lower than for the conventional chemotherapy group. Therefore, the administration of TS-1 leads to a reduction in medical costs.",
author = "Katsumi Tanaka and Tsutomu Kaetsu and Satoshi Suzuki and Mitsuo Kusano and Shuichi Yajima and Hiroyuki Sakamaki and Shunya Ikeda and Naoki Ikegami and Murayama, {Jun Ichiro}",
year = "2003",
month = "1",
language = "English",
volume = "30",
pages = "73--80",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacoeconomic study of chemotherapy for gastric cancer

T2 - analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy

AU - Tanaka, Katsumi

AU - Kaetsu, Tsutomu

AU - Suzuki, Satoshi

AU - Kusano, Mitsuo

AU - Yajima, Shuichi

AU - Sakamaki, Hiroyuki

AU - Ikeda, Shunya

AU - Ikegami, Naoki

AU - Murayama, Jun Ichiro

PY - 2003/1

Y1 - 2003/1

N2 - To evaluate the economic impact of TS-1, an oral fluoropyrimidine, on the treatment of gastric cancer, the medical costs required for TS-1 treatment were compared with those for the conventional chemotherapy employed before the launch of TS-1 in patients with advanced and recurrent gastric cancer. The medical costs for 13 patients receiving TS-1 and 10 patients undergoing the conventional chemotherapy were extracted from the ordering system data, and the costs were compared using the fee schedule of the Japanese national health insurance. The monthly medical costs for the TS-1 group and conventional chemotherapy group were 327, 640 +/- 47,647 (mean +/- SE) yen and 852,874 +/- 62,412 yen, respectively. Medical costs appeared to have decreased because TS-1 is an oral preparation, permitting an easy transfer from inpatient treatment to ambulatory treatment, and because only small amounts of medication and blood transfusion were used for supportive care. Consequently, the medical costs for the TS-1 group were significantly lower than for the conventional chemotherapy group. Therefore, the administration of TS-1 leads to a reduction in medical costs.

AB - To evaluate the economic impact of TS-1, an oral fluoropyrimidine, on the treatment of gastric cancer, the medical costs required for TS-1 treatment were compared with those for the conventional chemotherapy employed before the launch of TS-1 in patients with advanced and recurrent gastric cancer. The medical costs for 13 patients receiving TS-1 and 10 patients undergoing the conventional chemotherapy were extracted from the ordering system data, and the costs were compared using the fee schedule of the Japanese national health insurance. The monthly medical costs for the TS-1 group and conventional chemotherapy group were 327, 640 +/- 47,647 (mean +/- SE) yen and 852,874 +/- 62,412 yen, respectively. Medical costs appeared to have decreased because TS-1 is an oral preparation, permitting an easy transfer from inpatient treatment to ambulatory treatment, and because only small amounts of medication and blood transfusion were used for supportive care. Consequently, the medical costs for the TS-1 group were significantly lower than for the conventional chemotherapy group. Therefore, the administration of TS-1 leads to a reduction in medical costs.

UR - http://www.scopus.com/inward/record.url?scp=0037267879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037267879&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 73

EP - 80

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -